Veranova

At Veranova, saving and improving the lives of patients is our mission. To achieve this, we must have the cutting-edge infrastructure needed to enable the next generation of therapeutics. That's why we are building three new suites at our Devens, MA site. Watch the video below to find out more about the next step in our journey.

Don't miss Veranova's Global VP, Chemical Development Operations, William Sanders, in an upcoming webinar with Hanson Wade! Will will be discussing recent advances in ADC linker technology aimed at enhancing ADC stability in the bloodstream and reducing payload hydrophobicity. Register for the webinar on October 22: https://lnkd.in/e4DvvJXW

Veranova is pleased to announce the appointment of Joe Torres-Ocasio PE, MBA as Senior Vice President and Chief Operating Officer (COO). Joe is a seasoned executive with experience leading and transforming key divisions across pharma and healthcare. He will oversee Veranova’s global operations across Europe and North America, as well as the company’s Engineering, Environmental Health & Safety (EHS) and Supply Chain/Operational Excellence functions. Follow the link to read the press release in full: https://lnkd.in/grx5w_B2

In our recent Expert Insights article, Veranova's Senior Scientist, Alex Koval, explored the potential of tag-assisted liquid-phase peptide synthesis (LPPS) techniques in the manufacturing of peptide-based therapeutics. As the demand for these modalities increases, Veranova is committed to extending our chemical expertise in LPPS and delivering products with a more sustainable, efficient, and cost-effective approach for our customers. Read our Expert Insights article now: https://lnkd.in/echeXzBE

Whatever your drug development needs, Veranova has the technical capabilities to make your plans a reality. With expertise spanning the entire development pipeline, we can manage your challenges and accelerate your therapeutic to market with confidence. Watch the video below to find out more about our unique approach.

Our team members did us proud at the 2025 Cambridge Chariots of Fire relay yesterday! Mateusz Pitak, Ruth Lunt, Dyanne Cruickshank, Annemarie Humphreys, Paul Lewis, and Boe Claybourn had a great time running through the beautiful Cambridge colleges in aid of East Anglia's Children's Hospices (EACH). Well done to them, and to members of the wider team who came out to cheer them on. Take a look below to see our runners in action!

We were honored to welcome The Nobel Prize laureate, distinguished Professor of Chemistry at Stanford University, and Veranova Advisory Board member Carolyn Bertozzi to our SCALE 2025 Symposium in July. In a fascinating talk, Carolyn spoke about her pioneering decades-long work developing Bioorthogonal Chemistry (a term she coined) and Click Chemistry, and how these groundbreaking innovations are enabling the construction of complex therapeutic modalities across pharma today, including cancer drug development. Watch Carolyn’s talk in full here: https://lnkd.in/gCgekkcU

Want to learn more about optimal polymer selection for amorphous solid dispersions (ASDs)? If so, make sure to attend our upcoming webinar, delivered by our Principal Scientist, Thierry Bonnaud! Thierry will explore the role of ASDs in improving solubility during drug development, with a focus on the non-steroidal anti-inflammatory drug piroxicam. Sign up below to hear his insights at 16:00 CET on October 2. Register for the webinar today: https://lnkd.in/eKQPSUbq

The countdown to CPHI Frankfurt 2025 is on, and the Veranova team is excited to discuss the key innovations shaping the future of pharma. Leveraging 19 years of experience with multi-ADC linker-payload systems, we're ready to tackle your toughest development challenges — from ADCs and TIDES to highly potent APIs. Register for the event using the link below, and catch the team at Stand 6.0D44 from October 28-30. Secure a meeting with us at CPHI Frankfurt today: https://lnkd.in/gqDcGEPT

Managing complexity with confidence is what we do at Veranova. From pre-clinical to commercialization, we have the analytical expertise to help you unlock the potential of specialty modalities and drive your therapeutic to market. Find out more using the link below.